OBJECTIVE: The aim of this study was to investigate the relationship between plasma glutamate, glutamine and gamma-aminobutyric acid (GABA) levels in female patients with major depression treated with S-citalopram or fluoxetine. METHODS: The patients were assigned into S-citalopram (10 mg/day) or fluoxetine (20 mg/day) groups (n = 15 per group). The Hamilton and Beck Depression Inventory Scales were performed on all study participants, and blood samples were collected. The same procedures were repeated 10 days following the onset of therapy. Fifteen female healthy volunteers were also included in the study for the evaluation of normal plasma levels. RESULTS: The plasma GABA levels of the healthy volunteers were higher whereas those for glutamate and glutamine were lower than the day zero samples of the patients. An increase in plasma GABA levels and a decrease in glutamate and glutamine levels were observed on the 10th day of treatment. No difference was detected between the drug treatments. CONCLUSION: Our findings may suggest that GABA, glutamate and glutamine play a role in depression and that plasma GABA may be used as a biomarker for treatment control.
OBJECTIVE: The aim of this study was to investigate the relationship between plasma glutamate, glutamine and gamma-aminobutyric acid (GABA) levels in female patients with major depression treated with S-citalopram or fluoxetine. METHODS: The patients were assigned into S-citalopram (10 mg/day) or fluoxetine (20 mg/day) groups (n = 15 per group). The Hamilton and Beck Depression Inventory Scales were performed on all study participants, and blood samples were collected. The same procedures were repeated 10 days following the onset of therapy. Fifteen female healthy volunteers were also included in the study for the evaluation of normal plasma levels. RESULTS: The plasma GABA levels of the healthy volunteers were higher whereas those for glutamate and glutamine were lower than the day zero samples of the patients. An increase in plasma GABA levels and a decrease in glutamate and glutamine levels were observed on the 10th day of treatment. No difference was detected between the drug treatments. CONCLUSION: Our findings may suggest that GABA, glutamate and glutamine play a role in depression and that plasma GABA may be used as a biomarker for treatment control.
Authors: Gerard Sanacora; Graeme F Mason; Douglas L Rothman; Fahmeed Hyder; James J Ciarcia; Robert B Ostroff; Robert M Berman; John H Krystal Journal: Am J Psychiatry Date: 2003-03 Impact factor: 18.112
Authors: William Berger; Akhil Mehra; Maryann Lenoci; Thomas J Metzler; Christian Otte; Gary Tarasovsky; Synthia H Mellon; Owen M Wolkowitz; Charles R Marmar; Thomas C Neylan Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2010-07-17 Impact factor: 5.067
Authors: Dmitry Frank; Ruslan Kuts; Philip Tsenter; Benjamin F Gruenbaum; Yulia Grinshpun; Vladislav Zvenigorodsky; Ilan Shelef; Dmitry Natanel; Evgeny Brotfain; Alexander Zlotnik; Matthew Boyko Journal: Neuropharmacology Date: 2019-05-31 Impact factor: 5.250
Authors: Yaoyang Zhang; Michaela D Filiou; Stefan Reckow; Philipp Gormanns; Giuseppina Maccarrone; Melanie S Kessler; Elisabeth Frank; Boris Hambsch; Florian Holsboer; Rainer Landgraf; Christoph W Turck Journal: Mol Cell Proteomics Date: 2011-08-23 Impact factor: 5.911
Authors: Michiko Nakazato; Kenji Hashimoto; Ulrike Schmidt; Kate Tchanturia; Iain C Campbell; David A Collier; Masaomi Iyo; Janet Treasure Journal: Ann Gen Psychiatry Date: 2010-06-25 Impact factor: 3.455
Authors: Zhen Ren; Nadia Sahir; Shoko Murakami; Beth A Luellen; John C Earnheart; Rachnanjali Lal; Ju Young Kim; Hongjun Song; Bernhard Luscher Journal: Neuropharmacology Date: 2014-08-05 Impact factor: 5.250